For example, splicevariants of MICAL-2 are known to be clinically associated with prostatecancer, and contribute to the viability of prostate cancer cells.75 It would therefore be of interest to understandhow the patterns of in vivo methionine oxidation are altered in cellsexpressing the splice variant of MICAL-2. This evidence concerns the gene MICAL2 and prostate carcinoma.